To all Longs, I think there are several approaches to

New Post Public Reply Private Reply Replies (0) Message Board
curncman
474
To all Longs,

I think there are several approaches to COVID-19 underway and all of them are happening at the same time. One approach is to have vaccine going and of course that is complicated approach as vaccines take time to make and vaccine may elicit immunity in the body but also can make one feel more sick instead of preventing one from geting sick when exposed to COVID-19.

So a lot of work on research & safety has to be done. On the other side though there is also plethora of therapeutic drugs in development that offer as treatments to prevent the front line workmen from getting severely ill. Then there are questions are if one gets severely sick what treatments can be used to prevent you from dying.

TSOI has quickly re-positioned its 3 years of R&D to offer Neutraceuticals, Cellular Therapy approcches to treat the severe end of COVID-19 spectrum . How does COVID-19 kill you? Basically one gets drowned within the lungs. One's lungs get flooded with fluid which is called ARDS. How TSOI treats the ARDS without limiting the body's ability to clear the VIRUS .... thats a tricky question it turns out that our own stem cells may possess the ability to tone down that inflammation to reduce swelling of fluids in the lungs without inhibiting the bodys ability to clear the VIRUS.

Now as we wait for the PHASE II clinical trial of QUADRAMUNE already underway to be concluded in November 2020 timeframe. As we all know TSOI is still treating and enrolling patients who are severely sick in many hospitals all over USA and the name of the game is whether TSOI can prevent these patients from dying with suffering from late stage end symptons of COVID-19.

One other COVID-19 treatment approach that TSOI uses is supercharged DENDRITIC CELLS called STEMVACS ..TSOI has adopted this novel approach with allogeneic DENDRITIC cells which are like pills in a bottle and they are off-the-shelf and has tremendous potential to reach its target. Beyond COVID-19, TSOI is working on similar approaches to treat cancer, RA, Diabetes II and CTE/TBI and Mental Depression, Suicide.
So TSOI is exciting micro cap innovative biotech company is in good R&D position wise and ready to unleash innovative therapeutic products to treat COVID-19, SARS, ARDS.

In terms of other categories of treatment of COVID-19 other than vaccine, is a treatment like antidote called MAB (monoclonal Anti Bodies) i.e before one gets sick and that monoclonal Anti Body looks like can prevent the virus from getting you sick. Also several BIG pharma companies are also working on coming up with their own version of MABs. TSOI produces MABs which are highly efficacious and have the keys to bind with the immune system but also can be made in HUGE mass production to be able to have millions in numbers to tackle the fall/winter flu season that can hit US with more COVID-19 infection waves

Therapeutic Solutions International Inc (TSOI) Stock Research Links

TSOI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sirha Lyon® 2027: A New Chapter in Foodservice

Updated Category News Views 162

A Bold Step Forward There's a hearty aroma wafting from Lyon this January, and it's not just from the local gastronomy. Sirha Lyon® is queuing up for its 23rd edition, promising to turn the Foodservice and Hospitality sectors on their heads. Nearly 150,000 square meters of exhibition space packed to the rafters with over 4,300 exhibitors—this ain't your average trade...

Continue Reading
BCG Pinpoints Fatal Ignorance in Critical Mineral Risks

Updated Category News Views 0

Unseen Weakness in Industrial Giants Imagine staring right past a pothole while driving, then wondering why you keep popping your tires. That's where industrial companies find themselves today with critical minerals, according to a new wake-up call from Boston Consulting Group. The giant problem? Firms are blissfully unaware of the mosquitoes in their machines—tiny,...

Continue Reading
Fulcra Unveils DIY Web App Tool for AI Agent Users

Updated Category News Views 87

Fulcra Dynamics Pushes the Boundaries with New Tool There's always that moment when a company nudges the needle, and Fulcra Dynamics seems to have done just that with its latest release. They've unveiled an ingenious tool that promises a shake-up in how we build and use web applications with AI. It's the kind of move that makes you stop and wonder if we're witnessing the...

Continue Reading
Skechers Facing Class Action: Investors Urged to Act

Updated Category News Views 50

Skechers Under Fire: Fraud Allegations Surface Alright, if you've been around the stock block a while, you know these stories can often read like a suspense novel. Plot twist: Skechers U.S.A., Inc. (formerly NYSE: SKX) is now facing some serious accusations. There's a class action lawsuit claiming that some shady dealings went down during the company's $9.4 billion...

Continue Reading
Gildan's Troubling Legal Struggles: Investor Action Alert

Updated Category News Views 76

Gildan's Bumpy Ride: Legal Woes Unfold Well, folks, seems like Gildan Activewear Inc. (NYSE:GIL) is in for a bumpy ride, and not the kind that makes you feel alive, I tell ya. They've been slapped with a class action lawsuit, and the news ain't pretty. Accusations are flying hot about how they've been playing fast and loose with their financials. The Allegations: Channel...

Continue Reading
OncoHost's Research Links TKI Sensitivity to Biology

Updated Category News Views 163

Cracking the Code on TKI Sensitivity When it comes to medicine, sometimes the trickiest part is knowing which button to push—especially in the high-stakes world of metastatic renal cell carcinoma (mRCC). OncoHost just dropped a bombshell at the ESMO 2026 Congress about their new plasma proteomics model that lets us peer into what makes some patients click with Tyrosine...

Continue Reading
Bladex Declares Quarterly Dividend for Q3 2026

Updated Category News Views 61

Bladex's Steady Dividend: What's Under the Hood? Well, well, it looks like Bladex is doing the old dividend dance again. They've just announced a quarterly cash dividend of $0.6875 per share for the third quarter of 2026. It's scheduled for payout on November 24 to those who have their noses in the ledger come November 6—that's your record date, folks. Now, dividends...

Continue Reading
Post University Expands with New Tech and Health Degrees

Updated Category News Views 46

If you're looking to invest in an education with promising payoffs, you might look into what's cooking over at Post University. They've just dropped a bombshell of new programs sure to get some attention from tech heads and health nuts alike, and I can't help but think there's potential brewing here. New Academic Paths Emerge Post University isn't resting on its...

Continue Reading
Nucor's Q3 2026 Earnings: Strong Growth Amid Steel Surge

Updated Category News Views 89

Nucor's Solid Third Quarter Performance Nucor Corporation is flexing its muscles, reporting a robust third quarter for 2026. With net earnings hitting $1.32 billion and a diluted earnings per share of $5.80, the steel giant has shown it can more than hold its ground in a competitive market. Compare that to last quarter's $1.16 billion - we're seeing serious momentum....

Continue Reading
Surgery Partners Buyout: Fair Deal or Insider Jackpot?

Updated Category News Views 66

What's Going On With Surgery Partners? Alright, here's the scoop that shareholders can't ignore—Surgery Partners (NYSE:SGRY) could be heading under the scalpel itself with a proposed buyout by HealthSpan. For those holding onto SGRY stock, this might feel like watching the rerun of a medical drama where the ending ain't clear yet. Shareholders are set to get $23.50 a...

Continue Reading

Top 5 Most Recently Viewed Articles

Nanjing Medical University Marks Milestone with Celebrations

Updated Category News Views 59

Nanjing Medical University Celebrates a Landmark Anniversary Nanjing Medical University (NMU) recently observed its 90th anniversary with a series of memorable events at its Jiangning Campus. This celebration included a remarkable commemorative ceremony, an innovative development conference, a forum on medical education, and an exciting cultural gala that brought together...

Continue Reading
Revolutionary Gel Launch by Pelthos Therapeutics for Skin Care

Updated Category News Views 142

Pelthos Therapeutics Unveils groundbreaking treatment Pelthos Therapeutics Inc. (NYSE: PTHS) has recently made headlines by launching Zelsuvmi (berdazimer) topical gel 10.3%, an innovative treatment designed specifically for molluscum contagiosum, a highly contagious skin infection primarily affecting children but also adults. This product has been approved for home use...

Continue Reading
Investors Eye Future Gains as Sportradar Options Surge

Updated Category News Views 242

Understanding Sportradar Group AG's Current Options Activity Recently, there has been notable trading activity surrounding Sportradar Group AG (NASDAQ: SRAD), with options trades summing up to a substantial $476,040 detected by advanced algorithms. These figures hint at increasing investor engagement and interest in the company’s stock. What's particularly exciting is...

Continue Reading
GXO Logistics Sets Earnings Call for Fourth Quarter 2024 Insights

Updated Category News Views 91

GXO Logistics Plans Upcoming Earnings Call GXO Logistics, Inc. is preparing to hold its fourth quarter and full-year 2024 earnings conference call and webcast on a specified date in February 2025. This event is an important opportunity for investors and stakeholders to gain insight into the company's financial performance and strategic direction during a rapidly changing...

Continue Reading
Pimco Income Strategy Fund Achieves New Peak at $8.62

Updated Category News Views 143

Pimco Income Strategy Fund Reaches New Heights In an encouraging trading environment, the Pimco Income Strategy Closed Fund (PFL) stock soared, achieving an impressive 52-week high of $8.62. This milestone is a testament to the fund's remarkable recovery and the unwavering confidence of investors. Over the past year, PFL has showcased a commendable increase of 9.45%,...

Continue Reading